ClinicalTrials.gg
CompletedNCT00239395Updated Nov 1, 2013

A Study to Compare Meloxicam IM Once Daily and Meloxicam Administered Orally Once Daily in Patients With Osteoarthritis

A Phase 3 interventional study of Meloxicam ampoule and Meloxicam tablet in Osteoarthritis, sponsored by Boehringer Ingelheim. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 15 studies in Osteoarthritis by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Osteoarthritis · Boehringer Ingelheim.

Started
2004
with 1 other
Phase 3
2 of 15
none open now
Registered
1st of 15
by date

Among the 15 studies in Osteoarthritis by Boehringer Ingelheim, this one is one of 2 that started in 2004, is one of 2 in phase 3, and was the 1st registered.

Osteoarthritis

2,977 studies on the registry are indexed under Osteoarthritis; 437 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

None of the 15 studies in Osteoarthritis by Boehringer Ingelheim is open now. The open studies under Osteoarthritis, anywhere →

Who these studies take

Of the 284 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 30 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Osteoarthritis by Boehringer Ingelheim as a file.
02

Study summary

The objective of this trial was to assess the efficacy and safety of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.

Read the detailed description

This was a randomized (1:1), open-label, multi-center, active-control, parallel-group study to compare the efficacy of 7.5 mg meloxicam i.m. once daily compared with 7.5 mg meloxicam tablets once daily p.o. in patients with osteoarthritis over a time period of 7 days.

The primary endpoint: Pain on active movement,

The secondary endpoint:

  • Pain at rest
  • Patient status with regard to change of arthritic condition assessed by the patient/investigator
  • Patient's assessment of arthritic condition
  • Onset of action
  • Time to maximum pain relief
  • Paracetamol consumption
  • Withdrawals due to inadequate efficacy
  • Final global assessment of efficacy by the patient/investigator

Safety endpoints

  • Local tolerability assessment of the injections by the patient/investigator
  • Patient's /Investigator's assessment of overall tolerability
  • Number, nature and severity of adverse events
  • Laboratory investigations
  • Withdrawals due to safety reasons

Patients eligible for the trial who met all inclusion and exclusion criteria and who gave their informed consent were randomized to one of two treatment groups (i.e. meloxicam ampoule or meloxicam tablet).

The study period totaled 8-14 days included screening, randomisation, study drug administration, and 7-day follow-up. The relevant assessment were performed on the day of randomisation and 7-day follow up.

Study Hypothesis:

The null hypothesis of interest is that the primary endpoint for meloxicam ampoule is inferior to oral meloxicam. The alternative is that meloxicam ampoule is noninferior to the oral meloxicam .

Comparison(s):

The primary endpoint of the study was to assess pain on active movement by VAS prior and after the treatment.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 years or above
  • Patients suffering from acute and painful exacerbation of osteoarthritis of the hip or knee.

The diagnosis must be based on

  • clinical signs and symptoms or
  • x-ray diagnosis plus clinical signs and symptoms

    • Assessment of pain on active movement (by the patient) must exceed 40 mm on a 100 mm visual analogue scale (VAS)
    • Symptoms of OA requiring administration of NSAIDs
    • Willingness and ability to provide written .

Exclusion criteria

Exclusion Criteria:

  • Known or suspected to the trial drugs or their , analgesics, antipyretics or NSAIDs
  • Any clinical evidence of active peptic ulceration during the last six months
  • Pregnancy or breastfeeding (precaution : attention should be drawn to reports that NSAIDs were reported to decrease the effectivity of intrauterine devices)
  • Asthma, nasal polyps, angioneurotic oedema or urticaria following the administration of aspirin or NSAIDs
  • Concomitant treatment with anti-coagulants (including heparin), lithium
  • Concomitant administration of other NSAIDs or analgesic agents (except paracetamol up to 4g/day)
  • Administration of any NSAID during the last 2 days (3 days for any oxicam) prior to the first administration of the trial drug
  • Concomitant treatment with an oral initiated or with an altered dose over the previous month
  • Parenteral or intraarticular administration of corticosteroids in the previous month
  • Any i.m. injection during the previous 7 days
  • Any to i.m. injections
  • Clinical evidence of or known severe cardiac, hepatic, renal, metabolic, haematological disease, mental disturbance, ulcerative colitis
  • Any other rheumatological or non-rheumatological disease that could interfere with the evaluation of efficacy and safety
  • Serum creatinine 125 % of the ; aspartate transferase (/SGOT) and/or alkaline transferase (ALT/SGPT) 200 % of the upper limit of normal range
  • count \< 100,000/mm3 ; leucocytes count \< 3,000/mm3
  • Synovectomy in the previous month or during the trial
  • Participation in another clinical trial during this study or during the previous month
  • Previous participation in this trial
  • Patient unable to comply with the protocol
  • Concomitant therapy with specific symptomatic drug of OA, such as chondroitin sulphate, diacerhein, initiated or with an altered dose over the previous 3 months.
  • Intraarticular administration of hyaluronic acid in the previous month
  • Patients where physiotherapy will be changed throughout the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
168 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Pain on active movement by VAS.

    Time frame: day 0, day 7

Secondary outcomes

  1. Pain at rest

    Time frame: up to 7 days

  2. Patient status with regard to change of arthritic condition

    Time frame: up to 7 days

  3. Withdrawals due to inadequate efficacy

    Time frame: up to 7 days

  4. Onset of Analgesic action

    Time frame: up to 7 days

  5. Time to maximum pain relief

    Time frame: up to 7 days

  6. Paracetamol consumption

    Time frame: up to 7 days

  7. Final global assessment of efficacy by patient

    Time frame: up to 7 days

  8. Final global assessment of efficacy by investigator

    Time frame: up to 7 days

  9. Assessment of local tolerability

    Time frame: up to 7 days

  10. Nature and severity of adverse events

    Time frame: up to 7 days

  11. Change in other laboratory investigations

    Time frame: up to 7 days

  12. Withdrawals due to safety reasons

    Time frame: up to 7 days

  13. Patient's and investigator's assessment of overall tolerability

    Time frame: up to 7 days

07

Study locations

8 sites
  • People's Hospital, Beijing University
    Beijing, 100044, China
  • Beijing Xuan Wu Hospital
    Beijing, 100050, China
  • 1st Affiliated, Anhui Medical University
    Hefei City, Anhui Province, 230022, China
  • Qilu Hospital, Shang Dong University
    Nan City, 250012, China
  • Shanghai Renji Hospital
    Shanghai, 200001, China
  • Shanghai Zhongshan Hospital
    Shanghai, 200032, China
  • Shanghai Guanghai Hospital
    Shanghai, 200052, China
  • Shanghai Changhai Hospital
    Shanghai, 200443, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2004, a primary completion of Dec 2004 and a completion of Dec 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2005
First posted
Oct 17, 2005
Start
Jul 2004
Primary completionActual
Dec 2004
Completion
Dec 2004
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00239395
First posted
Oct 17, 2005
Start date
Jul 2004
Primary completion
Dec 2004
Completion
Dec 2004
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim Shanghai
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion